Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma

Related Experiment Video

Updated: Feb 22, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Xiaoping Liu1, Weiping Ma1, Yanli Yan1

  • 1Cancer Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, People's Republic of China.

Journal of Biochemical and Molecular Toxicology
|September 16, 2017
PubMed

Insights

High mobility group nucleosome-binding domain 5 (HMGN5) promotes esophageal squamous cell carcinoma (ESCC) progression and chemoresistance. Inhibiting HMGN5 may enhance ESCC treatment effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • High mobility group nucleosome-binding domain 5 (HMGN5) is implicated in tumorigenesis and multidrug resistance in various cancers.
  • The specific role of HMGN5 in esophageal squamous cell carcinoma (ESCC) is not well-defined.

Purpose of the Study:

  • To investigate the function of HMGN5 in ESCC.
  • To determine the impact of HMGN5 on ESCC cell growth, apoptosis, and chemoresistance.

Main Methods:

  • Quantitative analysis of HMGN5 expression in ESCC cells.
  • HMGN5 knockdown and overexpression experiments in ESCC cell lines.
  • Assessment of cell proliferation, apoptosis, and sensitivity to cisplatin.
  • Analysis of key gene expression including multidrug resistance 1, cyclin B1, and Bcl-2.

Main Results:

  • HMGN5 was significantly upregulated in ESCC cells.
  • HMGN5 knockdown inhibited ESCC cell growth and induced apoptosis.
  • Reduced HMGN5 expression increased sensitivity to cisplatin chemotherapy.
  • HMGN5 overexpression yielded opposite effects, promoting tumor progression.

Conclusions:

  • HMGN5 promotes tumor progression and chemoresistance in ESCC.
  • HMGN5 is a potential therapeutic target for improving ESCC treatment outcomes.
Keywords:
HMGN5chemosensitivitycisplatinesophageal squamous cell carcinoma

More Related Videos

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

4.1K
Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

867

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K